Erwan Bezard1, Elsa Y Pioli, Qin Li, Françoise Girard, Vincent Mutel, Charlotte Keywood, Francois Tison, Olivier Rascol, Sonia M Poli. 1. Motac neuroscience, Manchester, UK; Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Service de Neurologie, CHU de Bordeaux, Pessac, France; Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China.
Abstract
BACKGROUND: Blocking metabotropic glutamate receptor type 5 (mGluR5) has been proposed as a target for levodopa-induced dyskinesias (LID) in Parkinson's disease (PD). We assessed the effect on LID of dipraglurant, a potent selective mGluR5 receptor negative allosteric modulator in the gold-standard LID macaque model. METHODS: Dipraglurant (3, 10, and 30 mg/kg, by mouth) was tested in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) macaque model of LID in a four-way crossover, single-dose, controlled study (n = 8). RESULTS: Dipraglurant inhibited dyskinesias in the LID macaque model, with best effect reached at 30 mg/kg dose with no alteration of levodopa efficacy. CONCLUSION: Acute challenges of dipraglurant were efficacious on choreic and dystonic LID in the MPTP-macaque model. Dipraglurant pharmacokinetic variables were similar to those of levodopa, suggesting that both drugs can be co-administered simultaneously in further studies.
BACKGROUND: Blocking metabotropic glutamate receptor type 5 (mGluR5) has been proposed as a target for levodopa-induced dyskinesias (LID) in Parkinson's disease (PD). We assessed the effect on LID of dipraglurant, a potent selective mGluR5 receptor negative allosteric modulator in the gold-standard LID macaque model. METHODS: Dipraglurant (3, 10, and 30 mg/kg, by mouth) was tested in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) macaque model of LID in a four-way crossover, single-dose, controlled study (n = 8). RESULTS: Dipraglurant inhibited dyskinesias in the LID macaque model, with best effect reached at 30 mg/kg dose with no alteration of levodopa efficacy. CONCLUSION: Acute challenges of dipraglurant were efficacious on choreic and dystonic LID in the MPTP-macaque model. Dipraglurant pharmacokinetic variables were similar to those of levodopa, suggesting that both drugs can be co-administered simultaneously in further studies.
Authors: K-W Lee; L Westin; J Kim; J C Chang; Y-S Oh; B Amreen; J Gresack; M Flajolet; D Kim; A Aperia; Y Kim; P Greengard Journal: Mol Psychiatry Date: 2015-09-15 Impact factor: 15.992
Authors: Roberta Marongiu; Margarita Arango-Lievano; Veronica Francardo; Peter Morgenstern; Xiaoqun Zhang; M Angela Cenci; Per Svenningsson; Paul Greengard; Michael G Kaplitt Journal: Proc Natl Acad Sci U S A Date: 2016-01-19 Impact factor: 11.205
Authors: Wen Yuan Luo; Su Qian Xing; Ping Zhu; Chen Guang Zhang; Hui Min Yang; Nicholas Van Halm-Lutterodt; Li Gu; Hong Zhang Journal: Neurotherapeutics Date: 2019-07 Impact factor: 7.620
Authors: Anthony M Downs; Kaitlyn M Roman; Simone A Campbell; Antonio Pisani; Ellen J Hess; Paola Bonsi Journal: Neurobiol Dis Date: 2019-07-04 Impact factor: 5.996